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Abstract
Introduction Whether cancer stem cells occur in BRCA1-
associated breast cancer and contribute to therapeutic
response is not known.
Methods We generated and characterized 16 cell lines from
five distinct Brca1deficient  mouse mammary tumors with
respect to their cancer stem cell characteristics.
Results All cell lines derived from one tumor included increased
numbers of CD44+/CD24-  cells, which were previously
identified as human breast cancer stem cells. All cell lines
derived from another mammary tumor exhibited low levels of
CD44+/CD24- cells, but they harbored 2% to 5.9% CD133+
cells, which were previously associated with cancer stem cells
in other human and murine tumors. When plated in the absence
of attachment without presorting, only those cell lines that were
enriched in either stem cell marker formed spheroids, which
were further enriched in cells expressing the respective cancer
stem cell marker. In contrast, cells sorted for CD44+/CD24- or
CD133+ markers lost their stem cell phenotype when cultured in
monolayers. As few as 50 to 100 CD44+/CD24- or CD133+
sorted cells rapidly formed tumors in nonobese diabetic/severe
combined immunodeficient mice, whereas 50-fold to 100-fold
higher numbers of parental or stem cell depleted cells were
required to form few, slow-growing tumors. Expression of stem
cell associated genes, including Oct4, Notch1, Aldh1, Fgfr1,
and Sox1, was increased in CD44+/CD24- and CD133+ cells.
In addition, cells sorted for cancer stem cell markers and
spheroid-forming cells were significantly more resistant to DNA-
damaging drugs than were parental or stem cell depleted
populations, and they were sensitized to the drugs by the heat
shock protein-90 inhibitor 17-DMAG (17-
dimethylaminoethylamino-17-demethoxygeldanamycin
hydrochloride).
Conclusion  Brca1-deficient mouse mammary tumors harbor
heterogeneous cancer stem cell populations, and CD44+/
CD24- cells represent a population that correlates with human
breast cancer stem cells.
Introduction
BRCA1 was the first identified breast cancer susceptibility
gene and was localized to 17q21 by positional cloning more
than 15 years ago [1]. BRCA1 is mutated in about 2.5% to
5% of all breast cancers, in 45% of inherited breast cancer
families, and in up to 80% of breast/ovarian cancer families.
BRCA1 mutation is associated with a high incidence of bilat-
eral disease, and confers an 82% risk for developing breast
cancer and an 54% risk for developing ovarian cancer by age
80 years [2]. Somatic mutations of BRCA1  have been
reported in up to 10% of cases of sporadic ovarian cancer, but
they are extremely rare in sporadic breast cancer [3-5]. How-
ever, reduced BRCA1 protein expression is detected in high-
grade sporadic breast and ovarian tumors, suggesting that
epigenetic downregulation of BRCA1  contributes to their
aggressive clinical course [6-8]. The existence of cancer stem
cells associated with BRCA1  mutations or downregulation
has not been reported.
ABC = ATP-binding cassette; CI = Combination Index; 17-DMAG = 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride; IC50 = 
50% inhibitory concentration; MMTV = mouse mammary tumor virus; MTS = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium, inner salt; PBS = phosphate-buffered saline; RT-PCR = reverse transcription polymerase chain reaction.Breast Cancer Research    Vol 10 No 1    Wright et al.
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In spite of early detection and aggressive surgical and chemo-
therapeutic approaches, no significant 5-year survival benefits
have been achieved in patients harboring BRCA1 mutations
[6]. During the past several years, cancer stem cells have been
subjected to increasing scrutiny as a potential cause of
relapse and drug resistance [9]. Several groups [10,11] iden-
tified a small subpopulation of highly tumorigenic cells from
human breast tumors bearing the CD44+CD24-/low lineage
phenotype, which have drug-resistant phenotype and the
capacity to form tumors after transplantation in nonobese dia-
betic/severe combined immunodeficient mice. Subsequent
enrichment in Sca-1 positive cancer stem cells was shown for
mouse mammary tumor models, such as mouse mammary
tumor virus (MMTV)-Her2/neu and MMTV-Wnt1 [12], and
Thy1/CD24 expression further defined cancer stem cells in
the Wnt1 model [13]. No studies have yet been conducted to
characterize Brca1-deficient cancer stem cells.
Multiple mouse models with targeted deletion of Brca1 in the
mammary gland generate tumors with low penetrance [14].
Increased incidence of these tumors is observed in mice har-
boring two Brca1Δexon11 genes in a p53+/- background, with
uniform deletion of p53 in these tumors. Lymphomas were
also reported in this model [15]. However, the Brca1 deficient
mouse mammary tumors have variable penetrance and
latency, which makes it nearly impossible to use these models
to standardize therapies and to study the stem cell population.
To overcome these difficulties, we developed and character-
ized 16 cell lines from five independent Brca1Δexon11/p53+/-
tumors. We examined these cell lines for specific cell popula-
tions using multiple known stem cell markers. Cell populations
expressing putative stem cell markers were more resistant to
chemotherapeutic agents than were parental cells, and had
other characteristics of cancer stem cells, including reconsti-
tution of tumors by as few as 50 to 100 cells.
Materials and methods
Generation of cell lines from Brca1 mouse mammary 
tumors
Brca1 tumor cell suspensions were prepared as described by
Varticovski and coworkers [16] from Brca1Δ11p53+/- mammary
tumors. Briefly, mice were euthanized with CO2, and tumors
were collected aseptically and mechanically dissociated. Cells
were passaged through a 40 μm mesh screen, and were fur-
ther dissociated by serial passage through a syringe with 18
to 25 gauge needles. Cells were plated at low density for
selection of individual clones. Cells were grown at 37°C in 5%
carbon dioxide in RPMI 1640 media supplemented with peni-
cillin/streptomycin, glutamine, and fetal bovine serum starting
with 2% and progressively increasing to 10%. More than 40
clones were isolated using cloning cylinders and a total of 16
cell lines were developed from five independent primary
tumors. Each cell line was passaged weekly and maintained in
culture for up to 50 passages.
Characterization of unsorted cells that survive in long-
term cultures in the absence of attachment
The ability of cells to grow in the absence of attachment was
tested by plating cells on low-binding plates (Fisher Scientific,
Hampton, NH, USA). Under these conditions, some cell lines
showed surviving floating colonies that formed compact sphe-
roids after 3 to 4 weeks of culture. Spheroid formation fre-
quency for each cell line was tested by plating cells in limiting
dilution from 500 to 1 cell/well on 96-well low-binding plates
in sextuplicate. The number of colonies was scored weekly,
and the spheroids were dispersed into single cells and
upstaged to six-well plates after 3 weeks. To obtain single cell
suspension, spheroids were collected and washed in phos-
phate-buffered saline (PBS). Single cell suspension was
obtained by incubation in collagenase/dispase and DNAse
(Roche, Switzerland), filtering through a 40 μm filter to remove
remaining aggregates (Fisher Scientific), and plated directly
onto 96-well tissue culture plates for drug testing or passaged
onto a new low-binding plate for expansion.
Analysis of cell surface markers
Cell lines grown as monolayer were trypsinized, and cells
grown as spheroids were dispersed to obtained single cell
populations, as above. Cells were washed in PBS with 1%
bovine serum albumin and stained with PE anti-mouse CD24
(BD Pharmingen, San Jose, CA, USA), or APC anti-mouse
CD24 (Biolegend, San Diego, CA, USA), FITC anti-mouse
CD44 (Southern Biotech, Birmingham, AL, USA), or PE anti-
mouse prominin-I CD133 (eBioscience, San Diego, CA,
USA). Rat IgG (CHEMICON, Billerica, MA, USA) was used as
the isotype control, in accordance with the manufacturer's
instructions. Cells were analyzed by flow cytometry using LSR
II (BD Biosciences, San Jose, CA, USA). Data were collected
using FACSDiVa software (BD Biosciences) from no fewer
than 30,000 cells.
Cytotoxicity assay and calculation of combination index
Doxorubicin was obtained from Sigma (St. Louis, MO, USA)
and dissolved in PBS as 10 mmol/l stock. Aliquots were frozen
and diluted in media immediately before use. Cisplatin and
etoposide were obtained from Sigma-Aldrich (St. Louis, MO,
USA). 17-DMAG (17-dimethylaminoethylamino-17-demethox-
ygeldanamycin hydrochloride) was obtained from Invivogen
(San Diego, CA, USA). These drugs were dissolved in dime-
thyl sulfoxide, stored as 10 mmol/l stock aliquots, and diluted
in media immediately before use.
Cells were seeded in six replicates in 96-well plates at 10,000
cells per well. Serial dilutions of doxorubicin, cisplatin, etopo-
side, and 17-DMAG in medium were added to the cells on the
following day or as indicated. Dose-response curves to single
drugs at 24 hours, 48 hours, and 72 hours after exposure were
generated to determine the range of concentrations to be
used in combination. For drug interaction studies, drugs were
added sequentially (with the 17-DMAG introduced with a 24-Available online http://breast-cancer-research.com/content/10/1/R10
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hour delay) or simultaneously in a final volume of 100 μl. Cyto-
toxicity was measured using the Cell Titer 96 Aqueous One
Solution Cell Proliferation Assay (Promega, Madison, WI,
USA), which is a colorimetric method for determining the
number of viable cells based on bioreduction of the tetrazolium
compound MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-car-
boxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner
salt) by metabolically active cells. After exposure to a single
drug or after a total of 48 hours in sequential addition experi-
ments, 20 μl MTS reagent was added to each well and the
plates were incubated in a humidified 37°C incubator with 5%
carbon dixoide for 1 to 4 hours. Absorbance at 490 nm was
recorded using a 96-well plate reader. Data were averaged
and normalized against the average survivals of untreated sam-
ples and analyzed using CalcuSyn (Biosoft, Ferguson, MO,
USA), software based on the multiple drug-effect equation of
Chou and Talalay [17].
Tumor growth in vivo
All studies were conducted in an AAALAC (Association for
Assessment and Accreditation of Laboratory Animal Care
International) accredited facility, in compliance with the US
Public Health Service guidelines for the care and use of ani-
mals in research. Parental cells and cells sorted for indicated
cell surface markers were resuspended in 100 μl RPMI media
and injected into the inguinal mouse fat pad (pad #4) of 6- to
8-week-old female nonobese diabetic/severe combined immu-
nodeficient mice. The growth of tumors was monitored using
caliper measurements to determine tumor mass. Weights (mil-
ligrams) were calculated from measurements (millimeters) of
two perpendicular dimensions (length and width) using the
formula for a prolate ellipsoid and assuming a specific gravity
of 1.0 mg/mm3 [18].
RNA extraction and analysis of stem cell-associated 
genes
Total RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA), in accordance with the manufacturer's
instructions, followed by DNAse treatment and RNA clean-up
(RNeasy Mini Kit; Qiagen, Valencia, CA, USA). RNA concen-
tration and integrity was determined using the RNA 6000
Nano LabChip Kit (Qiagen) on Agilent 2100 Bioanalyzer.
The mRNA levels of 84 genes associated with stem cell biol-
ogy were examined using human Stem Cell RT2 profiler arrays
(SuperArray Bioscience, Frederick, MD, USA), in accordance
with the manufacturer's instructions. RNA (250 to 500 ng)
was reverse transcribed using the First Strand Synthesis Kit
(Qiagen), and cDNA was subjected to real-time PCR using
SYBR green/ROX Master Mix (Qiagen) and PCR cycles were
performed on a 7500 Real Time PCR System (Applied Biosys-
tems, Foster City, CA, USA). A dissociation curve was run as
a quality control using default melting curve settings. Values
obtained for the threshold cycle for each gene were normal-
ized using the average of housekeeping genes amplified on
the same array.
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR was used to measure mRNA
expression levels of selected mouse ATP-binding cassette
(ABC) transporters using LightCycler RNA Master SYBR
Green Kit and the LightCycler 480 instrument (Roche Bio-
chemicals, Indianapolis, IN, USA). Specific PCR primer
sequences for genes are listed in Additional file 1. All RT-PCR
reactions were performed on 200 to 400 ng total RNA with
250 nmol/l specific primers. Negative controls consisting of
no-template (water) reaction mixtures were run with all reac-
tions. Melting curves were determined for each primer set fol-
lowing all RT-PCR runs using the LightCycler 480 software.
Crossing points for each transcript were determined using the
second derivative maximum analysis with the arithmetic base-
line adjustment. Crossing point values for each transporter
were normalized to the respective crossing point values for ref-
erence gene Pmca4 (plasma membrane calcium ATPase 4)
[19]. Data are presented as fold change in gene expression
using the ΔΔCt method.
Immunostaining
Cells growing as spheroids were expanded in low-binding six-
well plates, collected, allowed to attach over 2 hours to a mul-
tiwell chamber coated with D-poly L-lysine, fixed in 4% para-
formaldehyde, and permeabilized with 0.3% Triton X-100 in
PBS (15 minutes) and washed in PBS. Cells were blocked in
donkey serum for 1 hour, and incubated with anti-Numb, anti-
Oct4, anti-Nestin, or anti-CD133 primary antibodies overnight
(Abcam, Cambridge, MA, USA). Secondary antibodies conju-
gated to Alexa Fluor 488 and Alexa Fluor 568 (Molecular
Probes, Eugene, OR, USA) were added for 1 hour, washed in
PBS, and mounted under a coverslip using Vectashield
Mounting Medium (Vector Laboratories, Burlingame, CA,
USA). Immunofluorescence was visualized in an Olympus
1X51 fluorescence microscope (Olympus America Inc.,
Center Valley, PA, USA.
Results
Characterization of cell lines from Brca1 mouse 
mammary tumors
Sixteen cell lines were generated from five independent origi-
nal  Brca1Δexon11/p53+/-  mouse mammary tumors [15,16].
These cells had similar doubling time of approximately 18 to
20 hours and similar morphology with epithelioid appearance,
although A1-derived cell lines had some rounded cells (Addi-
tional file 2). As previously described for Brca1 tumors in this
model [15], all original tumors and cell lines expressed mutant
Brca1Δexon11 and lacked p53, as determined by PCR (data not
shown). Several cell lines representing each one of the five
original tumors were selected at random for additional studies.Breast Cancer Research    Vol 10 No 1    Wright et al.
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To determine whether Brca1 cell lines contain a distinct pop-
ulation of cancer stem cells, we examined expression of cell
surface markers previously assigned to human breast cancer
stem cells, namely CD44 and CD24. All Brca1  clones
expressed CD44 to varying degrees, with the B.15 cell line
expressing the lowest percentage of positive cells (Figure 1a).
Expression of CD24 was also similar among the cell lines, but
higher in B.15 cells (Figure 1b). All cell lines derived from A1
tumor (A1.1, A1.8, and A1.10) exhibited a higher (1.32% to
5%) fraction of CD44+/CD24- cells, which correlate with the
phenotype of human breast cancer stem cells (Figure 1d).
We also tested whether Brca1 cells express CD133, a marker
not previously described in association with breast cancer, but
shown to mark cancer stem cells in other tumors. Only RP
tumor-derived cell lines had a significant CD133+ population,
which varied between 2% and 5.9%, as shown for RP.1 cell
line (Figure 1c). All other cell lines had low CD133+ popula-
tion. There was no overlap between CD133+ and CD44+/
CD24- populations, as determined by analysis of cells after tri-
ple staining (Additional file 3 [panels A and B]). Thus, individ-
ual Brca1-deficient mouse mammary tumors gave rise to cell
lines with distinct populations of cells expressing stem cell
markers. The studies described below address differences
and similarities between these putative cancer stem cell pop-
ulations, as defined by these two types of cell surface markers.
Cells that express stem cell markers survive and 
proliferate as spheroids in long-term cultures in the 
absence of attachment
A characteristic of cancer stem cells is their ability to grow in
three-dimensional structures in semisolid support or in liquid
Figure 1
Expression of putative stem cell markers from cells derived from five individual Brca1 tumors Expression of putative stem cell markers from cells derived from five individual Brca1 tumors. (a) Cell surface expression of CD44 is relatively uni-
form across all cell lines. The open histograms, outlined by a black line, represent positive staining for CD44, and gray filled histograms show nega-
tive controls stained with matched isotype antibody. (b) Expression of CD24 is variable, with highest level in B.15 cells. (c) There was substantial 
expression of CD133+ cells, accounting for 5.9% of the total population, among RP.1 cells. (d) Co-expression of CD44 and CD24 markers. The 
quadrants are gated to separate double positive, single positive, and double negative populations. The percentage of cells with CD44+/CD24- mark-
ers is indicated at the upper left of each panel. The highest fraction is in cells derived from A1 tumor, as represented by A1.8 cells. One of more than 
three independent experiments is shown here.Available online http://breast-cancer-research.com/content/10/1/R10
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culture in the absence of attachment, termed spheroids or
mammospheres. To determine the capacity of Brca1 cells to
form spheroids in the absence of attachment, we sorted A.8
cells for CD44+/CD24- cells (SC+) and CD44-/CD24+ (SC-)
populations. Cells were plated by limiting dilution from 500 to
1 cell/well in six replicate wells in low-binding 96-well plates.
Over 2 to 3 weeks, some cells and cell aggregates were
formed but degenerated, but many survived and formed tight
actively growing spheroids. The SC+ population exhibited a
significantly higher number of proliferating viable spheroids, as
compared with the SC- population, and generated spheroids
even when plated as a low as four to six cells/well (Figure 2a).
To determine whether these spheroids can be expanded in
vitro, the spheroids were dissociated into single cell suspen-
sions and passaged multiple times in long-term sphere-form-
ing assay. These cells repeatedly formed spheroids for up to
eight subsequent passages when plated in the absence of
attachment. Thus, the A1.8 cell line contains a population of
cells that survives in the absence of attachment and forms
spheroids that can be expanded in vitro.
Spheroids formed from unsorted cells are enriched in 
cells which express cancer stem cell markers
To determine the expression of putative cancer stem cell mark-
ers in the spheroids, we plated A1.8 and RP.1 cell lines with-
out prior sorting as single cells/well in low-binding 96-well
plates. The frequency of spheroid formation was 2% to 4%, as
expected from the fraction of cells expressing respective can-
cer stem cell markers in these cell lines. The resulting sphe-
roids were dissociated into single cells and expanded in 96-
well and then in six-well low-binding plates. Analysis of cells
derived from spheroids after multiple passages showed spon-
taneous enrichment in cells expressing putative cancer stem
cell markers. In addition, a distinct subpopulation of cells was
evident, namely a CD24-/low population (Figure 2b), which was
not previously observed in any of the parental cell lines (Figure
1b and data not shown). More than 10% of cells derived from
expanded A1.8 spheroids acquired a CD44+/CD24- pheno-
type (Figure 2b, lower panel) and more than 30% were
CD44+/CD24-/low. Similar observations were made for RP.1
cells, in which spheroids had 27.7% CD133+ cells after multi-
ple passages (Additional file 4).
To determine whether any of the other Brca1 cell lines can
grow in the absence of attachment, we plated each of the 16
cell lines in long-term spheroid-forming assay in limiting dilu-
tion, and as single cells/well. Cells were monitored for growth
and the number of spheroids was scored after 2 to 3 weeks in
culture. Cell morphology varied greatly, as shown for A1.1,
A1.8, B.15, P3.17, P2.1, and RP.1 cells after 2 weeks in cul-
ture (Additional file 5). Cell lines derived from B, P2, and P3
tumors had small aggregates and floating nonviable cells. In
contrast, all cell lines from A1 and RP.1 tumors had viable
spheroids in 96-well cultures, and proliferated vigorously as
spheroids after subsequent multiple passages in vitro. Coinci-
dently, these cell lines also exhibited a higher fraction of cells
in CD44+/CD24-  or CD133+  populations, respectively.
Because other cell lines failed to grow as spheroids, we did
not attempt to characterize the minute fraction of cells that
express CD44+/CD24- markers in those cell lines.
Cells sorted for putative stem cell markers repopulate 
the parental cell fractions after few passages in 
monolayer culture
We examined whether cells sorted for positive or negative
expression, or whether the putative stem cell makers maintain
their phenotypes when grown as monolayers in conventional
tissue culture dishes. A1.8 cells were sorted as 100%
CD44+/CD24- (SC+) or CD44-/CD24+ (SC-) populations and
plated as monolayer. Only 2.7% of SC+ cells retained CD44+/
CD24- phenotype after three passages, thus reconstituting the
1.32% to 5% fraction found in parental cells (Additional file 6
[panel A] and Figure 1). Furthermore, cells sorted from the
opposite quadrant for CD44-/CD24+ phenotype continued to
be depleted in CD44+/CD24- markers (0.05%). Thus, expan-
sion of CD44+/CD24- cells in monolayer leads to reconstitu-
tion of both CD44+/CD24- and CD44-/CD24+ cell fractions
found in parental cells, whereas cells depleted of CD44+/
CD24- cells were unable to repopulate the CD44+/CD24-
fraction.
Similarly, RP.1 cells sorted as 100% CD133+ cells exhibited
decreased expression after two passages in monolayer (Addi-
tional file 6 [panel B]), whereas cells depleted of the CD133+
population (sorted as 100% CD133-) were unable to reconsti-
tute the parental population and had a low fraction (0.6%) of
CD133+  cells. These data reveal that CD44+/CD24-  and
CD133+ cells have similar capacity for self-renewal and repop-
ulate cell fractions found in the respective parental cells.
Brca1 cells have variable sensitivity to DNA damaging 
agents
To establish the sensitivity of Brca1 cell lines to different drugs
frequently used to treat breast cancer patients, cell lines were
treated with different classes of DNA-damaging agents repre-
sented by doxorubicin, cisplatin, and etoposide. In addition,
we used a novel orally available molecular targeted agent,
namely 17-DMAG, which is a naturally occurring ansamycin
antibiotics derived from geldanamycin (GA, NSC 122750).
17-DMAG was tested because it affects multiple targets and
interferes with both cell survival and DNA repair pathways [20-
24]. All cells were relatively similar in their response to cispla-
tin, with a 50% inhibitory concentration (IC50) of 3 to 8 μmol/
l, and were variably sensitive to other agents (Additional file 7
and data not shown).Breast Cancer Research    Vol 10 No 1    Wright et al.
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Figure 2
Cells that express stem cell markers survive and form spheroid structures in the absence of attachment Cells that express stem cell markers survive and form spheroid structures in the absence of attachment. (a) Frequency of spheroid formation is 
increased in Brca1 A1.8 cells sorted for SC+ (CD44+/CD24-) as compared with SC- (CD24+/CD44-) populations. The results shown are from long-
term spheroid assay performed by limiting dilution. The black bars represent numbers of spheroids formed by CD44+/CD24- sorted cells/well and 
the white bars represent numbers from CD24+/CD44- cells ± standard deviation from six replicate wells at the end of 2 weeks in culture. The num-
bers on the ordinate show the number of cells plated/well. One of three independent experiments is shown. (b) Unsorted Brca1 A1.8 cells plated in 
the absence of attachment form spheroids, which are enriched in cells expressing stem cell markers. A1.8 were plated as single cells in low binding 
plates for 2 to 3 weeks, and the resulting spheroids were expanded for 4 subsequent passages, dispersed into single cell population, and stained 
with appropriate antibodies (as described in Materials and methods). The CD44 and CD24 markers are shown as an open histogram on the left, and 
filled histograms show negative controls stained with matched isotype antibody. The single stain analysis is on the right panel; the double staining is 
shown on the bottom. Results are presented as percentage of CD44+/CD24- cells from the total population. Note the appearance of a dual popula-
tion that contains CD24-/Low cells not evident in parental cells run side-by-side with the spheroid-derived cells and illustrated for the parental A1.8 
cell line in Figure 1. One representative experiment from more than three is shown here.Available online http://breast-cancer-research.com/content/10/1/R10
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Cells expressing stem cell markers and cells derived 
from spheroids are highly resistant to chemotherapeutic 
agents
We compared sensitivity to drugs of parental A1.8 cells, cells
dissociated from spheroids, and cells sorted for CD44+/
CD24-  (SC+) or CD44-/CD24+  (SC-) populations plated
immediately after sorting. Cells were treated side-by-side on
the following day with increasing concentrations of cisplatin
(Figure 3). Cells derived from spheroids were significantly
more resistant to cisplatin than parental cells, with IC50s of
16.675 μmol/l and 4.274 μmol/l, respectively (Figure 3a). In
addition, the SC- (CD44-/CD24+) population was significantly
more sensitive than was the parental or SC+ (CD44+/CD24-)
populations, with an IC50  of 1.384 μmol/l. Furthermore,
CD44+/CD24- (SC+) cells had an estimated IC50 of 45.846
μmol/l (Figure 3b), as calculated using CalcuSyn Software.
Because of gradual loss of stem cell markers in cells growing
as a monolayer, these data may further underestimate chem-
oresistance of the cancer stem cells. The morphology of each
cell fraction after 48 hours of exposure to 8 μmol/l cisplatin is
shown in Figure 3c. Although the parental and SC- population
exhibited significant signs of toxicity, SC+ cells have few signs
of toxicity and cells dispersed from spheroids showed small
aggregates, indicating a delay in cell growth, but remarkably
there were no significant signs of toxicity. Similar results were
obtained with parental RP.1 cells, spheroids, and cells sorted
for CD133+ and CD133- populations (data not shown).
Cells sorted for cancer stem cell makers lose their drug 
resistance when grown in monolayers
To determine whether cells sorted for putative cancer stem
cell markers lose the drug resistance after growing in monol-
ayers, sorted A1.8 CD44+/CD24-  (SC+), CD44-/CD24+
(SC-), and RP.1 CD133+ and CD133- cells were passaged
four times as monolayer. In addition to losing enrichment in
stem cell markers, as described above, these cells lost differ-
ences in sensitivity to cisplatin as compared with parental cells
(data not shown).
Expression of multidrug resistance genes in Brca1 stem 
cells
To determine whether drug resistance of cells expressing
stem cell surface markers is due to expression of multidrug
resistance genes, we compared expression of several
Figure 3
Brca1 cells expressing stem cell markers and cells growing as spheroids are highly resistant to cisplatin Brca1 cells expressing stem cell markers and cells growing as spheroids are highly resistant to cisplatin. A1.8 parental cells, cells from dispersed 
spheroids, and cells sorted for Stem Cell + (CD44+/CD24-) and Stem Cell – (CD44-/CD24+) markers were treated simultaneously with increasing 
concentrations of cisplatin for 48 hours. (a) Parental A1.8 cells (solid symbols) compared with spheroid-derived cells (open symbols). (b) A1.8 cells 
sorted as Stem Cell + (open symbols) and Stem Cell – (solid symbols) populations. (c) Morphologic appearance of control untreated cells and cells 
exposed to 8 μmol/l cisplatin, as indicated on each panel. Note the formation of aggregates from spheroid-derived dispersed cells at the end of 72 
hours in culture. One of three independent experiments is shown here.Breast Cancer Research    Vol 10 No 1    Wright et al.
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selected ABC transporters in five cell lines representative from
each primary tumor and compared their expression with
normal mammary gland from C57/Bl6 mice. Data were normal-
ized to expression of Pmca4, a housekeeping gene [19].
Using a panel of ABC transporters most likely to be responsi-
ble for drug resistance to the chemotherapeutic agents tested,
we included Abcb1a, Abcb1b, Abcc1, and Abcg2. Expression
of Abcg2 was higher in all cell lines except for P3.17. The high-
est level, with a 25-fold increase, was in B.15 cells, as com-
pared with expression in normal mammary gland (C57/Bl6;
Additional file 8 [panel A]). Thus, Abcg2 expression did not
correlate with the presence of stem cell population or with the
ability of cells to survive in the absence of attachment,
because B15 cells were more sensitive to all drugs, lacked
enrichment in stem cell markers, and did not form spheroids.
Remarkably, higher Abcb1b (Pgp, Mdr1) expression, but not
that of the other ABC transporters, was detected in cell lines
enriched in cancer stem cell markers, namely A1.8 and RP.1
(Additional file 8 [panel B] and data not shown).
We also compared expression of ABC transporters in parental
cell lines, spheroids, and cells sorted for positive or negative
stem cell markers, versus RNA levels in the respective original
A1 and RP Brca1 tumors (Additional file 8 [panels C and D]).
For Abcb1b, parental and sorted populations of A1.8 cells had
a substantial fivefold to ninefold increase in Abcb1 expression,
with the greatest increase in A1.8 parental and A1.8 SC+
sorted cells. In contrast, RP.1 CD133- and parental cells had
a fivefold increase when compared with the primary RP tumor,
whereas CD133+ cells and spheroids retained the expression
level found in the original RP tumor (Additional file 8 [panel C]).
Analysis of Abcg2 transporter (Additional file 8 [panel D]) in
A1.8 cells revealed higher levels in SC+ and parental cells than
in SC- or spheroids. RP.1 CD133- cells showed the highest
level of Abcg2, whereas RP.1 parental cell line, CD133+ frac-
tion, and spheroids showed fivefold increase as compared
with levels found in the original RP tumor. These data indicate
that expression of Abcb1, but not that of Abcg2, correlates
with drug resistance.
17-DMAG sensitizes Brca1 cells to chemotherapeutic 
agents
We also examined whether the heat shock protein (HSP)90
inhibitor 17-DMAG sensitizes Brca1 cells to DNA-damaging
agents and whether the schedule of administration plays a sig-
nificant role. Doxorubicin, cisplatin, or etoposide were added
simultaneously or sequentially, with 17-DMAG added 24
hours before or after DNA damaging agents. Calculation of
Combination Index (CI) was modeled by CalcuSyn software to
establish synergy or antagonism of the drug interaction. A CI
of 1 indicates an additive effect whereas under 1 reflects a
synergistic effect. For all cell lines and drugs tested, the com-
bination therapy was synergistic and more effective than either
drug alone, but no additional synergy was noted if 17-DMAG
was added 24 hours after cisplatin as compared with simulta-
neous treatment (Figure 4). Similar results were obtained
using doxorubicin and 17-DMAG (data not shown). In con-
trast, significant antagonism with CI above 1 was observed
when cells were exposed to 17-DMAG before cisplatin (not
shown). These data are consistent with previously reported G1
arrest induced by HSP90 inhibitors in other cancer cells,
which makes them highly resistant to DNA-damaging agents
[20].
We also examined whether the combination of cisplatin with
17-DMAG sensitizes the putative cancer stem cells to DNA-
damaging agents. Cells from A1.8 and RP.1 parental cells
sorted for respective stem cell positive and negative markers
were exposed to cisplatin and 17-DMAG simultaneously or
sequentially. Combination therapy was highly synergistic for all
drug doses, with CI significantly below 1, regardless of simul-
taneous or sequential (with 17-DMAG added 24 hours later)
schedule of administration (Figure 4c,d).
Tumor-initiating capacity of cells bearing stem cell 
markers
To determine whether cells that express distinct cancer stem
cell markers are tumorigenic in vivo, increasing numbers of
RP.1 (Figure 5a) and A1.8 (Figure 5b) cells sorted for expres-
sion of cancer stem cell markers were injected into mice, start-
ing with 50 cells/injection. Only two out of three mice that
received 5 × 103 CD133- RP.1 cells, and no mice injected with
1 × 103 cells or fewer formed tumors within 40 days (Figure
5a). In contrast, all cells sorted for the CD133+ marker were
highly tumorigenic, with tumors formed by as few as 50
CD133+ cells. In addition, the tumors generated from 5 × 103
CD133+ cells were at least 10-fold larger that the tumors
formed from the same cell number of CD133- cells at the end
of 40 days. Animals having no tumors were observed for an
additional 60 days. No mouse that received 50 or 100 CD133-
cells formed tumors or exhibited evidence of small tumors after
examination of the mammary gland after 60 days (not shown).
Four of a total of eight mice that received 5,000 cells and an
additional three out of nine mice that received 1,000 RP
CD133- cells had small tumors, measuring on average less
than 200 mm3, after 2 months.
Although tumors formed by A1.8 cells grew slower than did
RP.1 tumors, A1.8 CD44+/CD24-  cells were also highly
enriched in tumor-initiating cells, and 50 to 100 cells were suf-
ficient to generate tumors in 60 days (Figure 5b). Statistical
analysis of multiple experiments conducted in these cells,
summarized in Figure 5c, confirms the enrichment of RP.1
CD133+ and A1.8 CD44+/CD24- populations in tumor-initiat-
ing cells. These in vivo tumorigenesis studies for both cell
types indicate that Brca1 cells bearing distinct cancer stem
cell markers are enriched at least 50-fold to 100-fold in tumor-
initiating cells.Available online http://breast-cancer-research.com/content/10/1/R10
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Molecular characterization of Brca1 cancer stem cells
To determine whether Brca1 cells that express putative stem
cell markers express other genes that are characteristic of
stem cells, we compared RNA levels of stem cell associated
genes in cells sorted for positive and negative expression of
stem cell markers. Of 84 genes from the SuperArray panel, 11
genes were higher in A.8 CD44+/CD24- (SC+) than in CD44-
/24+ (SC-) cells, and 18 genes were higher in RP.1 CD133+
than in CD133- cells, as determined by real-time quantitative
PCR (Table 1). There was a remarkable overlap among stem
Figure 4
17-DMAG is synergistic with cisplatin for Brca1 parental and cancer stem cells 17-DMAG is synergistic with cisplatin for Brca1 parental and cancer stem cells. Cells were treated with increasing concentrations of cisplatin, 17-
DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), or a combination of both drugs at a constant 1:3 ratio. (a) Simulta-
neous treatment for 48 hours. The open circles and dotted lines represent exposure to 17-DMAG, the filled circles and dotted lines represent expo-
sure to cisplatin as single agents, and the filled squares linked by a solid line show combination. (b) Sequential addition of the drugs. The filled 
circles show exposure for 48 hours to cisplatin, the open circles and dotted lines represent 24 hours pf exposure to 17-DMAG, and the filled 
squares linked by a solid line show combination. The ordinate indicates concentrations of cisplatin, and the error bars represent ± standatd deviation 
from sextuplicates wells of one of more than three independent experiments. (c) Visual representation of Combination Index (CI) for each combina-
tion calculated using CalcuSyn Software. The closed circles represent simultaneous treatment and the open circles represent sequential addition of 
cisplatin followed by 17-DMAG. Values of CI below 1 indicate synergy, values above 1 represent antagonism, and CI = 1 corresponds to an additive 
effect. (d) 17-DMAG sensitizes parental and cancer stem cells to Cisplatin. CI for cisplatin and 17-DMAG added simultaneously (+) or sequentially 
(→) to parental cells or cells sorted for putative cancer stem cell markers. Data are derived from more than three independent experiments.Breast Cancer Research    Vol 10 No 1    Wright et al.
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cell genes over-expressed in both cell types, with seven
shared genes, including Notch1,  Fgfr1,  CD44, and Sox1.
Other genes whose over-expression was common between
CD44+/CD24- and CD133+ cells included Aldh1a1 (encod-
ing aldehyde dehydrogenase), which was previously associ-
ated with hematopoietic, skin, and CD133+ neuronal stem
cells [25]. Genes different between cancer stem cell popula-
tions in A1.8 and RP.1 cells included KRT15, a marker of basal
breast cancer type [26], with 17-fold higher expression in
RP.1 CD133+, and Desert hedgehog, with 4.3-fold higher
expression in the A1.8 SC+ than in the SC- population.
To validate our gene expression findings and to define further
the two types of cancer stem cells, we conducted immunoflu-
orescence studies on spheroids derived from A1.8 and RP.1
cells using antibodies to common and unique stem cell asso-
ciated gene products. As seen in Figure 6, spheroids from
both cell lines were positive for Oct4, a common key marker of
pluripotency. CD133 and Numb, a marker associated with
asymmetric division, were present in RP.1 but not in A1.8
spheroids, which confirmed the data obtained by real-time
quantitative PCR described above, and both were negative for
Nestin, which is a marker of early neuronal differentiation (data
Figure 5
Cells sorted for expression of CD44+/CD24- or CD133+ markers are enriched in tumor-initiating cells Cells sorted for expression of CD44+/CD24- or CD133+ markers are enriched in tumor-initiating cells. Tumor initiating capacity was determined by 
implantation of 50, 100, 500 or 1,000 cells in mouse fat pad (MFP) #4 of nonobese diabetic/severe combined immunodeficient mice. (a) RP.1 
CD133+ cells compared with RP.1 CD133- cells, and (b) A1.8 CD44+/CD24- cells compared with parental cells. Tumor growth rates were moni-
tored, as described in Materials and methods, and average tumor size is shown for each cell type and cell number implanted based on triplicate 
implantations. (c) Total number of mice that grew tumors, as determined from independent experiments performed for each cell line. The percent-
ages of positive tumors are indicated in parentheses.Available online http://breast-cancer-research.com/content/10/1/R10
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not shown). These data suggest that, in spite of having distinct
and nonoverlapping cell surface makers, the A1.8 and RP.1
cells have significant similarities in expression of stem cell
genes.
We also examined the expression of estrogen receptor 1 in
tumors and cell lines and compared it with expression in nor-
mal C57BL6 mice virgin mammary gland. The primary tumors
and corresponding cell lines exhibited lower estrogen recep-
tor 1 expression, with threefold to fivefold lower expression in
A.8 and RP.1, and 22-fold decrease in B.15 cells (Additional
file 9 and data not shown). These data are consistent with a
previously published report of decreased estrogen receptor
expression in fully developed Brca1 tumors [27].
Discussion
Cell lines derived from individual Brca1  mouse mammary
tumors had distinct and non-overlapping populations of puta-
tive cancer stem cell markers CD44+/CD24- and CD133+.
Only cell lines that contained a significant fraction of cells with
these markers formed spheroid structures without preliminary
sorting, and expansion of these spheroids in vitro led to further
spontaneous enrichment in cells with stem cell makers. In
addition, cells sorted for cancer stem cell markers and cells
growing as spheroids were significantly more resistant to
chemotherapeutic agents than were parental cells, and were
highly tumorigenic in mice. Two conclusions can be derived
from these studies. First, Brca1-deficient mouse mammary
tumors contain heterogeneous populations of cells that share
cancer stem cell properties. Second, some Brca1-deficient
tumors contain CD44+/CD24-/Low cells, previously associated
with human breast cancer stem cells [10,11,28], whereas oth-
ers contain CD133+ cells previously associated with tumors in
other organs [29]. Which population provides a closer corre-
late to human disease requires further study.
Human and murine cancer cell lines contain a small fraction of
cells that have cancer stem cell properties. These cells are
Table 1
Expression of stem cell genes in cells that express stem cell 
markers
Gene A1.8: SC+/SC- RP1: CD133+/CD133-
T >20 4.6
Sox1 19.2 2.2
Aldh1a1 3.5 3.2
Fgfr1 3.2 2.1
Tert 1.2 4.4
Notch1 2.5 4.1
CD44 1.9 3.4
Ascl2 7.2
Pdx1 7.1
Acan 6.6
Dhh 4.3
ALDH2 3
MME 4.5
KRT15 17
JAG1 2.2
FOXa1 19
DLL1 6
DLL3 3
COL9a1 3
CDH1 11
CD8B 6
CCNA2 2.5
Expression of genes from a panel of 84 stem cell-associated genes 
was determined by SuperArray real-time PCR using RNA from A1.8 
and RP.1 cells sorted for CD44, CD24, or CD133 markers (SC+ 
and SC-). For a complete list of genes tested, see [48]. The results 
are expressed as fold increase in cells sorted positive over negative 
markers from replicate experiments. Data are normalized to five 
housekeeping genes, as per the manufacturers' instructions. Genes 
common for both cell lines are presented at the top.
Figure 6
Cells growing as spheroids express stem cell proteins Cells growing as spheroids express stem cell proteins. Immunofluores-
cence of spheroids formed by A1.8 and RP.1 cells after four passages 
were stained for Numb, Oct4, and CD133. Cells growing as spheroids 
were allowed to attach to an eight-well slide, fixed, and stained with 
indicated antibodies. Staining for Oct4 is visualized in both cell lines, 
whereas expression of Numb and CD1333 is evident only in RP.1 cells.Breast Cancer Research    Vol 10 No 1    Wright et al.
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drug resistant, express stem cell associated genes, and have
high capacity for reconstituting tumors in vivo [9,28,30,31].
Because they constitute a very small cell fraction, their charac-
terization requires isolation, usually by sorting based cell sur-
face markers, and expansion in vitro. Our data confirm that
cells sorted for cancer stem cell markers reconstitute the
parental population after a limited number of passages in vitro.
Repopulation is indicative of self-renewal, presumably by
asymmetric division, and is consistent with stem cell-like prop-
erties of these cells. However, the expansion of sorted stem
cells in vitro results in rapid reduction in the cell fraction that
expresses stem cell phenotype, which complicates in vitro
studies of cancer stem cell biology and development of spe-
cific therapies.
Other investigators have reported that cancer-initiating cells
sorted from established cell lines or primary tumors form sphe-
roids when plated in semisolid support or serum-free media
supplemented with epidermal grwoth factor and basic fibro-
blast growth factor [9]. Breast cancer-derived spheroid struc-
tures have been termed mammospheres and have similarities
to those derived from normal mammary glands. Neurospheres
derived from neural tissues or gliomas grow in similar condi-
tions [32]. Brca1 tumor cells sorted for expression of putative
stem cell markers formed spheroids in the absence of attach-
ment without supplementation with growth factors. Further-
more, neither sorting nor growth factor supplementation was
required for generation of spheroids from unsorted Brca1 cell
lines that had a substantial population of cells expressing stem
cell markers. The unsorted cells that grew spheroids in long-
term culture were significantly enriched in stem cell makers
and were highly resistant to DNA-damaging agents after
multiple passages in vitro. Whether other cancer cells that
ordinarily grow in monolayer can survive in the absence of
attachment and form spheroids, and become enriched in can-
cer stem cells remains to be established.
In contrast to the orderly transition of normal stem cells
through differentiation with generation of progenitor and termi-
nally differentiated cells, multistep carcinogenesis is likely to
generate heterogeneity in cancer-initiating population, which
is reflected in different cell surface markers that identify cancer
stem cells in different tumor types. Previous studies corrobo-
rate that BRCA1 deficiency results in genetic instability asso-
ciated with centrosome amplification, defective cell cycle
checkpoint control, and impaired DNA damage repair [33,34].
We found that that same Brca1-deficient genetic background
gave rise to mammary tumors with two distinct and non-over-
lapping populations of cells that bear cell surface markers pre-
viously assigned to tumor-initiating cells from human breast
and other organs. Differences in cancer stem cell populations,
which constitute a minute fraction of total tumor, may underlie
some of the difficulties in using the genome-wide approach to
characterizing molecular profiles for these tumors.
Previous studies showed that 200 CD44+/CD24-/Low human
breast cancer cells reconstitute the entire population of
cancer cells in vitro and form tumors in vivo, whereas larger
numbers of parental cells or cells sorted for the absence of
these markers are needed to generate smaller, slower growing
tumors [10,11,28]. We found that CD44+/CD24- Brca1-defi-
cient mouse mammary tumor cells have cancer stem cell char-
acteristics in vitro, and 50 of these cells are sufficient to initiate
tumors in mice.
CD44 is a complex, multispanning, transmembrane glycopro-
tein whose expression correlates with drug resistance and
poor prognosis in many malignancies [35]. In addition to
hyaluronic acid, CD44 binds fibrinogen, fibronectin, collagen,
laminin, fibroblast growth factor-2, other heparin-binding
growth factors, and osteopontin, an inflammatory cytokine that
is associated with metastatic progression. Recent reports
suggested heterogeneity in human breast cancer stem cells
that express CD44 [36,37]. Whether CD44 expression plays
a direct role in drug resistance by activating multiple survival
pathways via growth factor receptors or integrin-mediated
'inside-out' signaling is not known and warrants further
investigation.
Although expression of CD24 negatively correlated with stem
cell characteristics in human breast cancer [10,11,28], the sit-
uation is more complex in mouse mammary tumors. In murine
mammary gland the CD24low cells correspond to myoepithelial
cells and have high mammary fat pad reconstitution capacity,
whereas the CD24+ population has low capacity for reconsti-
tution and is devoid of normal mammary stem cells [34]. Fur-
thermore, Weinberg and colleagues [39] recently reported
that mammosphere-forming and tumor-initiating capacities
reside within CD24+ freshly isolated normal mammary cells,
but when these cells are briefly cultured the CD24- population
was enriched with cancer stem cells. These previously
reported differences in expression of CD24 in different tumor
types and in normal mouse mammary epithelium support our
search for the role of CD24- cells in combination with a more
established marker, CD44, in BRCA1-deficient tumors.
Expression of CD133 in cancer-initiating cells is well docu-
mented for brain, prostate, and colon cancers [29] but has not
been described in breast cancer. We detected 2% to 4% of
CD133+ cells in multiple cell lines derived from one Brca1
tumor with characteristics similar to those found in CD44+/
CD24- cells, including drug resistance, the ability to form sphe-
roids with further 30% enrichment in CD133+  cells,
expression of stem cell genes, and in vivo reconstitution of
tumors with as few as 100 cells. CD133, also known as pro-
minin-1, is a cell-surface glycoprotein with five transmembrane
domains and two large glycosylated extracellular loops that
localize to membrane protrusions [29]. The function of CD133
in cancer stem cells has not been established, but one alterna-
tively spliced form binds cholesterol and thus may be involvedAvailable online http://breast-cancer-research.com/content/10/1/R10
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in Hedgehog signaling, which is required for primitive cell dif-
ferentiation and epithelial-mesenchymal interactions [40].
We previously described generation of tumors from cell sus-
pensions from multiple genetically engineered mouse mam-
mary tumors and their expansion by transplantation in naïve
recipients in vivo [16]. Gene expression analysis of individual
Brca1 mammary tumors and their subsequent passages in
vivo  revealed substantial heterogeneity in gene expression
[40], as predicted by differences in frequency and identity of
cancer stem cell populations in cell lines derived from these
tumors. Thus, in contrast to other models, such as MMTV-
PyMT and MMTV-wnt1, in which pooling individual mouse
tumors can generate sufficient material for basic and
translational studies [16,42], Brca1 tumors will need to be
analyzed individually and these studies are limited by the size
of each original tumor. Thus, generation of cell lines provided
valuable reagents for these studies.
A fundamental characteristic of cancer stem cells is their
resistance to chemotherapeutic agents. Much understanding
of BRCA1 drug resistance comes from studies of a single
human cell line, namely H1937, which is null for the BRCA1
gene. Although replacement of this gene increases resistance
to vinorelbine and cisplatin, it does not change sensitivity to
other agents, such as docetaxel [43,44]. This suggests that
other mechanisms may determine drug resistance in that cell
line. Consistent with these observations, we found that H1937
cells contain a significant (2% to 3%) population of cells
expressing CD44+/CD24- and no detectable CD133+ (data
not shown). The contribution of these cells to drug sensitivity
remains to be determined.
Over-expression of several ABC transporters has been linked
to drug resistance. Our analysis showed that Abcb1b expres-
sion correlated with an increase in cells having stem cell mark-
ers in A1.8 and RP.1 cell lines. Expression of Abcb1b was
further enriched in A.8 cells sorted for stem cell markers. How-
ever, this did not occur in RP.1 cells, because CD133- cells,
but not CD133+ cells, exhibited greater expression of Abcb1b.
Increased Abcg2 expression, previously associated with can-
cer stem cells, was evident in all Brca1 cell lines, regardless of
presence or absence of putative stem cell fraction. Further-
more, the highest expression of Abcg2 was detected in B.15,
a cell line that was not enriched in stem cell markers and did
not form spheroids. Thus, expression of other transporters, or
different drug resistance mechanisms, such as aldehyde dehy-
drogenase, which was over-expressed in both CD44+/CD24-
and CD133+ cell types, may be operational in Brca1 cancer
stem cells. Aldehyde dehydrogenase-1 participates in oxida-
tion of retinol to all-trans  retinoic acid, and confers drug
resistance to chemotherapeutic agents by an uncertain mech-
anism [45].
We previously demonstrated schedule-dependent synergy of
the HSP90 inhibitor 17-DMAG with doxorubicin for lymphoma
cells [20]. Here, we found that addition of 17-DMAG simulta-
neously or after chemotherapeutic agents sensitizes Brca1
cancer stem cells to three types of DNA-damaging agents:
doxorubicin, cisplatin, and etoposide. Because HSP90 inhibi-
tors impair multiple signal transduction pathways, resulting in
decreased cell survival and DNA repair [20,24,46], our data
showed that functional inactivation of Brca1 is particularly vul-
nerable to this combination. Whether HSP90 inhibitors sensi-
tize other cancer stem cells to chemotherapeutic agents
remains to be established. Development of cancer stem cell-
directed therapies has been hampered by inability to expand
cancer stem cells in vitro. Enrichment of cancer stem cells in
spheroids formed by Brca1 cell lines provides ample material
for studies of cancer stem cell biology and preclinical testing.
Conclusion
Brca1-deficient mouse mammary tumors harbor heterogene-
ous cancer stem cell populations, and CD44+/CD24- cells
also identify human breast cancer stem cells. In addition, long-
term spheroid-forming assay may allow rapid screening of
tumors for enrichment in cancer stem cells, identification of
additional stem cell markers, and development of potentially
curative therapies that target the putative cancer stem cell.
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File showing the morphologic appearance of all 16 cell 
lines developed from five original independent Brca1 
mammary tumors (A1, B, P3, P2, and RP) grown in 
monolayer.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S2.pdf
Additional file 3
File showing that expression of putative stem cell 
markers (CD44+/CD24- and CD133+) occurs on distinct 
and non-overlapping cell populations. (A) A1.8 cells 
stained simultaneously with antibodies for CD44, CD24, 
and CD133 (upper panel). The lower panel shows 
compensated dual staining for CD44/CD133, CD44/
CD24, and triple staining for all three markers. Only 
0.02% of A1.8 cells express all 3 markers. (B) RP.1 cells 
were stained and analyzed as above. No cells bearing all 
three markers are detectable. One of two independent 
analyses is shown here.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S3.ppt
Additional file 4
File showing that RP.1 cells growing as spheroids in the 
absence of attachment are enriched in CD133+ cells. (A) 
Parental cells and (B) cells dissociated from spheroids 
after expanding for four passages in vitro were stained 
side-by-side for CD133 and examined by fluorescence-
activated cell sorting. The percentage of CD133+ cells is 
indicated in each box. Note that a distinct CD133High 
population is now evident in spheroid-derived cells. One 
of three independent experiments is shown here.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S4.ppt
Additional file 5
File showing the morphologic appearance of unsorted 
cells plated in the absence of attachment from six cell 
lines that represent five individual tumors. A1.1, A1.8, 
B.15, P3.17, P2.1, and RP.1 cells were grown in 96-well 
low-binding plates for 2 weeks, dispersed into single 
cells, and expanded in six-well low-binding plates. One of 
more than three independent experiments is shown here.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S5.pdf
Additional file 6
File showing differences in frequency of CD44/CD24 
cells in A1.8 cell line that were growing in monolayer as 
compared to spheroids. (A) Fluorescence-activated cell 
sorting (FACS) analysis of stem cell markers from 
unsorted A1.8 parental cells is compared with SC+ 
(CD44+/CD24-) and SC- (CD44-/CD24+) cells sorted 
by FACS after growing as monolayers in the third 
passage (P.3). (B) RP.1 parental and CD133+ and 
CD133- cells sorted and passaged as monolayer twice 
(P.2) before analysis. One of three independent 
experiments is shown.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S6.ppt
Additional file 7
File showing the sensitivity of Brca1 cell lines to 
doxorubicin, cisplatin, and the HSP90 inhibitor 17-
DMAG. Cytotoxicity is determined by MTS assay for four 
representative Brca1 cell lines: A1.8, P3.17, B.15, and 
RP.1. Cells were exposed to increasing concentrations 
of (A) doxorubicin, (B) cisplatin, and (C) the HSP90 
inhibitor 17-DMAG. Percentage survival (± standard 
deviation from six replicate wells) after 24 hours of 
exposure to drugs is represented by open symbols and 
dotted lines, and after 48 hours by solid symbols and 
lines. The ordinate shows concentrations of individual 
drugs. One of three independent experiments for each 
cell type is shown here.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S7.ppt
Additional file 8
File showing the differences in expression of ABC 
transporters, Abcg2 and Abcb1, detected among the 
cell lines and parental tumors. (A) Expression of Abcg2 
among six Brca1 cell lines. (B) Expression of Abcb1 in 
five cell lines that represent each one of the five 
independent tumors. Relative (C) Abcb1 and (D) Abcg2 
expression in parental cells, cells sorted for respective 
stem cell markers, and unsorted cells growing as 
spheroids. Expression of each transporter is normalized 
to Pmca4 housekeeping gene, as described in Materials 
and methods. The bars represent ± standard deviation 
from triplicate samples. One of three independent 
experiments is shown.
See http://www.biomedcentral.com/content/
supplementary/bcr1855-S8.pptAvailable online http://breast-cancer-research.com/content/10/1/R10
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